At a glance
Different study purposes need different conclusions: an acute GH response supports a pharmacology observation, while a clinical endpoint requires a suitable controlled trial.
Identity & scope
Ipamorelin is the named GH-releasing peptide and ghrelin-receptor agonist used in these studies. A compound name does not establish a supplier product’s composition or delivery.
What the research shows
- The pharmacokinetic study characterized the relationship between exposure and GH release.
- The bowel-surgery trial provides an important negative efficacy result alongside the hormone literature.
Critical interpretation
Pharmacology and clinical efficacy answer different questions
The healthy-volunteer study characterises how ipamorelin exposure relates to a GH-release episode. The bowel-surgery trial instead asks whether a defined intervention improves a functional recovery measure. That trial did not show a significant meal-tolerance benefit. Its small proof-of-concept design does not exclude every possible effect, but it also cannot be cited as positive efficacy evidence. Reading the two papers together prevents a hormone response from standing in for a clinical result. [1] [2]
The nasal evidence has an explicit species boundary
The route-comparison study measured ipamorelin absorption in male rats. It helps identify a formulation question worth investigating, but does not establish human exposure. Differences in peptide, species and delivery preparation matter even within this small family of secretagogues. A human infusion experiment and a rat nasal experiment cannot be combined into a verified human nasal treatment effect. That would require evidence connecting the actual formulation to measured exposure and an appropriate outcome. [3]
Limitations & uncertainties
- These studies do not establish improved muscle strength or exercise recovery.
- Short clinical studies cannot establish the safety or effectiveness of another route or a commercial blend.
Open research questions
- Which endpoint is the proposed research intended to measure?
- Does a source test ipamorelin alone or a combination, and does its formulation match the material under investigation?
Selected papers & source records
Download bibliography1. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (opens in a new tab)
Gobburu JV, Agersø H, Jusko W, Ynddal L. (1999). Pharmaceutical Research. DOI: 10.1023/a:1018955126402 (opens in a new tab) · PMID 10496658
- Design & population
- Dose-escalation infusion experiment with eight healthy male volunteers at each of five exposure levels.
- What the study found
- A short GH-release episode followed ipamorelin exposure; the investigators developed a model relating drug concentration to GH response.
- Limits on interpretation
- A pharmacokinetic and hormone-response study, without a strength, body-composition or recovery efficacy endpoint.
2. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (opens in a new tab)
Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. (2014). International Journal of Colorectal Disease. DOI: 10.1007/s00384-014-2030-8 (opens in a new tab) · PMID 25331030
- Design & population
- Multicentre double-blind placebo-controlled phase 2 trial after bowel surgery;117 patients enrolled,114 included in the safety and modified intention-to-treat populations.
- What the study found
- The key meal-tolerance endpoint and secondary efficacy analyses did not differ significantly from placebo.
- Limits on interpretation
- Small proof-of-concept study with diverse underlying surgical conditions. It cannot establish effectiveness for a different indication or catalogue formulation.
3. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption (opens in a new tab)
Johansen PB, Hansen KT, Andersen JV, Johansen NL. (1998). Xenobiotica. DOI: 10.1080/004982598238976 (opens in a new tab) · PMID 9879640
- Design & population
- Comparative pharmacokinetic experiment in male rats using different administration routes for ipamorelin and related peptides.
- What the study found
- The study measured nasal uptake of ipamorelin in rats and differences in clearance and excretion between peptides.
- Limits on interpretation
- Animal absorption data, not a human nasal efficacy study. Species, formulation and delivery differences prevent assigning this exposure result to a commercial spray.
Search & review scope
Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.
Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.
Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.
Recorded search terms
- site.pubmed.ncbi.nlm.nih.gov ipamorelin randomized postoperative ileus trial
- site.pubmed.ncbi.nlm.nih.gov "9879640"
- site.pubmed.ncbi.nlm.nih.gov "ipamorelin" "bioavailability"
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. Ipamorelin: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/ipamorelin.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.